Entacapone

Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM) . Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

Product Specifications

CAS Number

[130929-57-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H413

Target

COMT

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/entacapone.html

Purity

99.97

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |H2O : 2 mg/mL (ultrasonic; adjust pH to 10 with NaOH)

Smiles

O=C(N(CC)CC)/C(C#N)=C/C1=CC([N+]([O-])=O)=C(O)C(O)=C1

Molecular Formula

C14H15N3O5

Molecular Weight

305.29

Precautions

H315, H319, H335, H413

References & Citations

[1]E Nissinen, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346 (3) :262-6.|[2]Shiming Peng, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med